Notizie Newsletter

23 Agosto 2019

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

Aug 13, 2019 - The European Commission has expanded the approval of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic leukemia (CLL), and also in combination with rituximab for the treatment of adult ...
Leggi tutto

29 Luglio 2019

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Enzalutamide, a potent androgen-receptor inhibitor, has demonstratedsignificant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide inmetastatic hormone-sensitive prostate cancer (mHSPC). ARCHES ...
Leggi tutto

29 Luglio 2019

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer A Phase 2 Trial

Patients with oligometastatic non–small cell lung cancer (NSCLC) may benefit from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies were conducted before the advent of immunotherapy, and a strong biological rationale for the ...
Leggi tutto

29 Luglio 2019

The association between metformin and ovarian cancer survival: a systematic review and meta-analysis of cohort studies

A number of observational studies examined the association between metformin therapy and ovarian cancer survival outcomes, but the results are inconsistent. To investigate the effect of metformin on survival for ovarian cancer patients. PubMed, Embase and Web of Science ...
Leggi tutto

29 Luglio 2019

TAS-102 Nears EU Approval for Gastric Cancer

July 26, 2019 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed approval of TAS-102 (trifluridine/tipiracil) for the treatment of adult patients with metastatic gastric cancer, including adenocarcinoma of the gastroesophageal ...
Leggi tutto

29 Luglio 2019

First ‘histology-independent’ treatment for solid tumours with a specific gene mutation

July 26, 2019 - EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for larotrectinib for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase ...
Leggi tutto

29 Luglio 2019

26 luglio 2019 – Sunset Clause – Warning di prossima decadenza del 26 luglio 2019

26 Luglio 2019

Fear of Cancer Recurrence: A Model Examination of Physical Symptoms, Emotional Distress, and Health Behavior Change

Fear of cancer recurrence is highly prevalent among adult survivors of cancer. The role of fear of recurrence in the emotional distress of survivors of cancer, as well as health behaviors that may directly affect their health, remains unclear. To advance oncology practice, ...
Leggi tutto

26 Luglio 2019

Has the Quality of Patient-Provider Communication About Survivorship Care Improved?

The aim of the current study was to assess whether the quality of patient–provider communication on key elements of cancer survivorship care changed between 2011 and 2016. Participating survivors completed the 2011 or 2016 Medical Expenditure Panel Survey Experiences ...
Leggi tutto

26 Luglio 2019

No Man Is an Island: Reflections From an ASCO IDEA Recipient

July 25, 2019 - IT WAS a chilly Chicago morning, and I was sitting at the lobby of my hotel when I saw a smiling gentleman cheerfully waving at me from his car. It was Lawrence H. Einhorn, MD, picking me up for our drive to Indiana. I was one of the recipients of the ASCO ...
Leggi tutto

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Ibrutinib EU Indications Expanded in CLL and Waldenstrom Macroglobulinemia

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer A Phase 2 Trial

The association between metformin and ovarian cancer survival: a systematic review and meta-analysis of cohort studies

TAS-102 Nears EU Approval for Gastric Cancer

First ‘histology-independent’ treatment for solid tumours with a specific gene mutation

26 luglio 2019 – Sunset Clause – Warning di prossima decadenza del 26 luglio 2019

Fear of Cancer Recurrence: A Model Examination of Physical Symptoms, Emotional Distress, and Health Behavior Change

Has the Quality of Patient-Provider Communication About Survivorship Care Improved?

No Man Is an Island: Reflections From an ASCO IDEA Recipient